Finemedix Statistics
Total Valuation
Finemedix has a market cap or net worth of KRW 41.98 billion. The enterprise value is 39.40 billion.
Market Cap | 41.98B |
Enterprise Value | 39.40B |
Important Dates
The last earnings date was Wednesday, August 13, 2025.
Earnings Date | Aug 13, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Finemedix has 5.43 million shares outstanding. The number of shares has increased by 8.81% in one year.
Current Share Class | 5.43M |
Shares Outstanding | 5.43M |
Shares Change (YoY) | +8.81% |
Shares Change (QoQ) | +0.66% |
Owned by Insiders (%) | 37.29% |
Owned by Institutions (%) | n/a |
Float | 2.63M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 3.96 |
PB Ratio | 2.17 |
P/TBV Ratio | 2.19 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 205.71, with an EV/FCF ratio of -12.28.
EV / Earnings | -68.08 |
EV / Sales | 3.72 |
EV / EBITDA | 205.71 |
EV / EBIT | n/a |
EV / FCF | -12.28 |
Financial Position
The company has a current ratio of 6.78, with a Debt / Equity ratio of 0.14.
Current Ratio | 6.78 |
Quick Ratio | 4.20 |
Debt / Equity | 0.14 |
Debt / EBITDA | 14.61 |
Debt / FCF | -0.87 |
Interest Coverage | -7.38 |
Financial Efficiency
Return on equity (ROE) is -3.70% and return on invested capital (ROIC) is -2.60%.
Return on Equity (ROE) | -3.70% |
Return on Assets (ROA) | -2.37% |
Return on Invested Capital (ROIC) | -2.60% |
Return on Capital Employed (ROCE) | -3.58% |
Revenue Per Employee | 151.38M |
Profits Per Employee | -8.27M |
Employee Count | 70 |
Asset Turnover | 0.51 |
Inventory Turnover | 1.20 |
Taxes
Income Tax | -441.84M |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | 7,574.40 |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 50.19 |
Average Volume (20 Days) | 76,092 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Finemedix had revenue of KRW 10.60 billion and -578.67 million in losses. Loss per share was -115.74.
Revenue | 10.60B |
Gross Profit | 5.72B |
Operating Income | -794.35M |
Pretax Income | -1.02B |
Net Income | -578.67M |
EBITDA | 191.51M |
EBIT | -794.35M |
Loss Per Share | -115.74 |
Balance Sheet
The company has 5.38 billion in cash and 2.80 billion in debt, giving a net cash position of 2.58 billion or 475.42 per share.
Cash & Cash Equivalents | 5.38B |
Total Debt | 2.80B |
Net Cash | 2.58B |
Net Cash Per Share | 475.42 |
Equity (Book Value) | 19.30B |
Book Value Per Share | 3,554.52 |
Working Capital | 11.45B |
Cash Flow
In the last 12 months, operating cash flow was -2.38 billion and capital expenditures -833.23 million, giving a free cash flow of -3.21 billion.
Operating Cash Flow | -2.38B |
Capital Expenditures | -833.23M |
Free Cash Flow | -3.21B |
FCF Per Share | -590.89 |
Margins
Gross margin is 53.98%, with operating and profit margins of -7.50% and -5.46%.
Gross Margin | 53.98% |
Operating Margin | -7.50% |
Pretax Margin | -9.63% |
Profit Margin | -5.46% |
EBITDA Margin | 1.81% |
EBIT Margin | -7.50% |
FCF Margin | n/a |
Dividends & Yields
Finemedix does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -8.81% |
Shareholder Yield | n/a |
Earnings Yield | -1.38% |
FCF Yield | -7.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Finemedix has an Altman Z-Score of 6.9 and a Piotroski F-Score of 2.
Altman Z-Score | 6.9 |
Piotroski F-Score | 2 |